Core Viewpoint - Ten stocks showed gains on Monday, defying a generally pessimistic market, as investors bought shares ahead of dividend payments and considered analyst ratings and macroeconomic factors [1][2]. Group 1: Stock Performances - NIO Inc. (NYSE:NIO) saw a 3.77% increase in share price, closing at $5.51, as investors anticipated first-quarter vehicle delivery updates [4]. The company aims to deliver between 80,000 and 83,000 vehicles in Q1, representing a year-on-year increase of approximately 90.1% to 97.2% [5]. NIO targets revenue growth of 103.4% to 109.2% year-on-year, estimating revenues between $3.5 billion and $3.6 billion [6]. - Dow Inc. (NYSE:DOW) experienced a 2.57% rise in share price, closing at $41.87, driven by news of a petrochemical shortage amid Middle East tensions [8]. The CEO indicated that supply shortages could lead to inflationary effects across various industries [9]. Dow reported a net loss of $2.6 billion last year, down from a net income of $1.1 billion, with net sales decreasing by 7% to $39.97 billion [10]. - Americold Realty Trust Inc. (NYSE:COLD) increased by 4.75% to $11.46, as investors prepared for an upcoming dividend payment of $0.23 per share [11]. The company reported a widened net loss of 21.4% to $114.5 million and a 2.4% decline in total revenues to $2.60 billion [12]. - Palo Alto Networks Inc. (NASDAQ:PANW) rose by 4.99% to $154.35, following the CEO's acquisition of additional shares worth $10 million [15]. The company launched a new security product, Prisma AIRS 3.0, aimed at securing AI applications [17][19]. - Insmed Inc. (NASDAQ:INSM) gained 5.52% to close at $153.32, following a price target upgrade from Morgan Stanley to $212, reflecting optimism for its Brinsupri bronchiectasis treatment [20][21]. The treatment has already been prescribed by 85% of surveyed pulmonologists, with expectations for patient share to increase significantly [22].

Core Viewpoint - Lipella Pharmaceuticals Inc. has filed for voluntary relief under Chapter 11 of the U.S. Bankruptcy Code to maximize value for creditors through a 363 sale process [1]. Group 1: Chapter 11 Filing - The company has initiated a Chapter 11 filing in the U.S. Bankruptcy Court for the Western District of Pennsylvania [1]. - The company plans to seek "first-day" relief to continue day-to-day operations, including maintaining cash management systems and paying employee wages and benefits [2]. Group 2: Restructuring Process - The company will provide updates throughout the restructuring process as necessary [2]. - Additional information regarding the Chapter 11 filing, including court filings and case information, may be available through the court's docket [4].

Astellas R&D Day Pioneering science to change tomorrow March 31, 2026 1 ©2026 ASTELLAS PHARMA INC. AND ITS AFFILIATES. Cautionary statement regarding forward-looking information In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These statements are based on management's current assumptions and beliefs in light of the information c ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff, representing other class members [2]. - The lawsuit alleges that Inovio made false and misleading statements regarding the manufacturing of its CELLECTRA device and the prospects of its INO-3107 Biologics License Application (BLA) [4]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience and resources [3]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [3].

Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. for allegedly misleading investors regarding the approval status of its New Drug Application for Anaphylm, leading to significant stock price declines [2][7]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals and entities who purchased or acquired Aquestive securities between June 16, 2025, and January 8, 2026 [2]. - Investors have until May 4, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that during the class period, the defendants created a false impression that Aquestive was on track to receive approval for Anaphylm by the January 31, 2026, Prescription Drug User Fee Act (PDUFA) date [7]. - The FDA identified deficiencies in Aquestive's NDA for Anaphylm, which precluded labeling discussions and delayed the approval process [7]. - Following the announcement of these deficiencies on January 9, 2026, the stock price of Aquestive fell over 37%, from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, 2026 [7]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the case are encouraged to contact the law firm for more details [4]. - There is no cost or obligation for investors to inquire about their rights or interests related to the lawsuit [4]. Group 4: About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation [5]. - The firm has offices in New York, South Carolina, and California, and handles cases in both federal and state courts [5].

Core Insights - Curanex Pharmaceuticals is advancing its lead asset, Phyto-N, towards an Investigational New Drug (IND) submission for ulcerative colitis planned for Q4 2026, while also exploring additional therapeutic opportunities [2][6][12] Operational Highlights - The company has made significant progress in manufacturing and chemistry, manufacturing, and controls (CMC) activities, including the completion of a pilot-scale GMP batch of Phyto-N to support GLP toxicology studies [4] - A dose-range finding toxicology study in rats and dogs has been completed, identifying the maximum feasible dose with no significant adverse findings, which is crucial for the design of the pivotal GLP toxicology program [5] Regulatory Pathway - Curanex is on track to submit its first IND application for ulcerative colitis in Q4 2026, contingent on the completion of required studies and regulatory review, with plans to initiate Phase 1 clinical development in Australia [6] Intellectual Property - The company has expanded its intellectual property position by filing a Patent Cooperation Treaty (PCT) application in March 2025, covering various therapeutic areas including autoimmune diseases and viral infections [7] Pipeline Development - Beyond ulcerative colitis, Curanex is evaluating additional therapeutic opportunities across a multi-indication pipeline, which includes atopic dermatitis, COVID-19, diabetes, NAFLD, and gout [8][9] Funding Position - Following its IPO, Curanex believes it has sufficient funding to support its near-term development objectives for at least the next twelve months, allowing continued advancement of IND-enabling activities and regulatory preparations [10] Strategic Vision - The CEO emphasized the company's commitment to building a robust operational foundation and pursuing regulatory approvals for differentiated therapeutic assets to address significant unmet medical needs [3][11]

Core Viewpoint - Investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period may have the opportunity to lead a securities fraud lawsuit due to alleged misleading statements regarding the company's drug trials [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx provided investors with overly positive information about the expected results of its Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta (OI) [5]. - Defendants allegedly made confident statements about setrusumab's ability to reduce fracture rates in OI patients while concealing material adverse facts about the drug's true efficacy and the risks associated with the study protocols [6]. - The lawsuit asserts that these misleading statements led to Ultragenyx securities being purchased at artificially inflated prices, resulting in investor losses when the true information became public [6]. Group 2: Class Action Participation - Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, are encouraged to join the class action lawsuit, with a lead plaintiff deadline set for April 6, 2026 [1][3]. - Participation in the class action does not require any out-of-pocket fees, as compensation is arranged through a contingency fee structure [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][7].

Core Insights - Ensysce Biosciences reported significant clinical and regulatory advancements in 2025, particularly with the initiation of the Phase 3 trial for PF614 and constructive dialogue with the FDA regarding its manufacturing pathway [2][3] - The company aims to introduce safer opioid medications through its innovative technologies, including the Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms [3][17] Program Updates - The PF614 drug candidate is designed to provide effective pain relief while minimizing the potential for abuse through its unique activation mechanism [3][6] - Enrollment in the pivotal Phase 3 clinical trial (PF614-301) for PF614 has commenced, focusing on post-surgical pain management [4][5] - The PF614-MPAR combines TAAP™ with MPAR® technology to provide overdose protection, demonstrating efficacy in clinical studies [6][7] - Ensysce is also developing PF9001 as a treatment for opioid use disorder (OUD), supported by grants from the National Institute on Drug Abuse (NIDA) [8] Intellectual Property Expansion - A new patent for the MPAR® technology has been allowed, extending intellectual property protection until 2042 [9][10] - Ensysce is exploring applications of its technologies beyond opioids, including potential treatments for ADHD and methadone alternatives for OUD [10] Financial Results - As of December 31, 2025, Ensysce reported cash and cash equivalents of $4.3 million, an increase from $3.5 million in 2024 [11] - Federal grants totaled $1.9 million in Q4 2025, up from $1.3 million in the same quarter of 2024, while total funding for the year was $5.1 million [12] - Research and development expenses rose to $10.4 million for the year, primarily due to increased clinical programs [13] - The net loss for Q4 2025 was $2.8 million, an improvement from a loss of $3.6 million in Q4 2024, with a total net loss of $10.2 million for the year [16][22]

Core Viewpoint - Artelo Biosciences, Inc. has successfully closed a private placement of common stock and warrants, raising approximately $11.0 million in gross proceeds, which will be used for working capital and debt repayment [1][3]. Group 1: Offering Details - The private placement involved 3,188,407 shares of common stock and warrants to purchase up to 6,376,814 shares, priced at $3.45 per share [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for this offering [2]. - The potential additional gross proceeds from the warrants, if fully exercised, could amount to approximately $20.4 million [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for working capital, general corporate purposes, and repayment of certain bridge debt [3]. Group 3: Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing therapeutics that modulate lipid-signaling pathways, addressing unmet needs in various medical conditions [6].

Core Insights - Bristol Myers Squibb is launching three medications on TrumpRx.gov with discounts ranging from 40% to 90% off retail prices [1] - The drug Sotyktu, used for treating moderate-to-severe plaque psoriasis, will be available for $743, a 90% discount from its retail price of $7,135.55 [1] - Zeposia, for relapsing forms of multiple sclerosis, will be offered at a discount between 88% and 90% [4] - Orencia SC, a weekly injection for moderate-to-severe rheumatoid arthritis, will see a 40% price reduction [5] - The initiative is part of ongoing efforts by the White House to reduce healthcare costs amid pressure from the Trump administration [5][11] Company and Industry Developments - Bristol Myers Squibb's new offerings follow the addition of Amgen and GSK to the list of companies providing discounts on TrumpRx.gov [7] - Amgen's medications will be available at an 80% discount, with Amjevita priced at $299 from an original price of $1,484 [8] - Other Amgen drugs, Aimovig and Repatha, will have discounts of 62%, while GSK's Incruse will be discounted by 55% [10] - The White House continues to push for more pharmaceutical companies to join the initiative as Americans seek ways to lower medical costs [11] - Data indicates that under the Biden administration, prescription drug costs increased by 10.4% from January 2021 to January 2025, contrasting with a mere 0.2% increase during the Trump administration [12]